A possible future strategy for NASH therapeutics may be to combine the depletion of MCT1 in stellate cells to decrease fibrosis with a potent anti-steatosis target such as DGAT2 (Yenilmez et al., 2022; Calle et al., 2021; Loomba et al., 2020) which we and others have shown is effective in reducing steatosis when depleted. Here, SLC16A1 is linked to steatosis.